China National Pharmaceutical Group Corporation: Potassium Chloride Injection Passes Generic Drug Consistency Evaluation.

China National Pharmaceutical Group announced that the potassium chloride injection of its wholly-owned subsidiary, China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd., has passed the generic drug quality and efficacy consistency evaluation. This drug is a commonly used medication for supplementing potassium in the body, mainly used for the treatment and prevention of hypokalemia. The sales revenue of public medical institutions nationwide in 2023 was 619 million yuan. China National Pharmaceutical Group Rongsheng has accumulated research and development investment of approximately 1.6354 million yuan. The evaluation will help expand the product market and sales, but there is uncertainty in its impact on performance.